Home>>Signaling Pathways>> Neuroscience>> Gap Junction>>AT-1002

AT-1002 Sale

目录号 : GC31538

AT-1002是一种6聚体合成肽,是一种紧密连接的调节剂和吸收增强剂。

AT-1002 Chemical Structure

Cas No.:835872-35-0

规格 价格 库存 购买数量
250mg 待询 待询
500mg 待询 待询

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

AT-1002, a 6-mer synthetic peptide[1], is a tight junction regulator and absorption enhancer[2].

AT-1002, a 6-mer synthetic peptide, belongs to an emerging novel class of compounds that reversibly increase paracellular transport of molecules across the epithelial barrier. AT-1002 can undergo Cys-Cys dimerization[1].Undifferentiated Caco-2 cells are treated with AT-1002 (0 to 5 mg/mL, 3 or 24 hours) and viability is assessed by measuring cellular ATP content. Treatment with AT-1002 for up to 3 h does not affect cell viability at any concentration. In particular, the viability of Caco-2 cells is not affected by 5 mg/mL AT-1002. AT-1002 reduces cell viability after 24 h at concentrations of 2.5 mg/mL and higher. However, the cells remain viable after 24 h if the cells are washed after exposure to AT-1002 for 3 h indicating that AT-1002 does not irreversibly damage cells[2].|| Cell Viability Assay[2]||Cell Line:|Caco-2 cells|Concentration:|0 to 5 mg/mL |Incubation Time:|3 or 24 hours|Result:|Treatment for up to 3 h did not affect cell viability at any concentration. Reduced cell viability after 24 h at concentrations of 2.5 mg/mL and higher.

[1]. Li M, et al. Structure-activity relationship studies of permeability modulating peptide AT-1002. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4584-6. [2]. Gopalakrishnan S, et al. Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer. Int J Pharm. 2009 Jan 5;365(1-2):121-30.

Chemical Properties

Cas No. 835872-35-0 SDF
Canonical SMILES N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CS)C(N[C@@H]([C@H](CC)C)C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O
分子式 C32H53N9O7S 分子量 707.88
溶解度 Soluble in DMSO 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.4127 mL 7.0633 mL 14.1267 mL
5 mM 0.2825 mL 1.4127 mL 2.8253 mL
10 mM 0.1413 mL 0.7063 mL 1.4127 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer

Tight junctions (TJs) are intercellular structures that control paracellular permeability and epithelial polarity. It is now accepted that TJs are highly dynamic structures that are regulated in response to exogenous and endogenous stimuli. Here, we provide details on the mechanism of action of AT-1002, the active domain of Vibrio cholerae's second toxin, zonula occludens toxin (ZOT). AT-1002, a hexamer peptide, caused the redistribution of ZO-1 away from cell junctions as seen by fluorescence microscopy. AT-1002 also activated src and mitogen activated protein (MAP) kinase pathways, increased ZO-1 tyrosine phosphorylation, and rearrangement of actin filaments. Functionally, AT-1002 caused a reversible reduction in transepithelial electrical resistance (TEER) and an increase in lucifer yellow permeability in Caco-2 cell monolayers. In vivo, co-administration of salmon calcitonin with 1 mg of AT-1002 resulted in a 5.2-fold increase in AUC over the control group. Our findings provide a mechanistic explanation for AT-1002-induced tight junction disassembly, and demonstrate that AT-1002 can be used for delivery of other agents in vivo.

Structure-activity relationship studies of permeability modulating peptide AT-1002

AT-1002 a 6-mer synthetic peptide belongs to an emerging novel class of compounds that reversibly increase paracellular transport of molecules across the epithelial barrier. The aim of this project was to elaborate on the structure-activity relationship of this peptide with the specific goal to replace the P2 cysteine amino acid. Herein, we report the discovery of peptides that exhibit reversible permeability enhancement properties with an increased stability profile.

Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002

Topical use of small interfering RNA (siRNA) as a therapeutic nucleic acid is increasingly studied for the treatment of skin diseases and for the improvement of skin properties. However, naked siRNA transdermal delivery is limited by its low stability in the body and low permeability into target cells. This is due to various skin barriers such as the stratum corneum that has multiple lipid bilayers and epidermal layers that have tight junctions. In this study, we investigate non-invasive transdermal siRNA delivery using two functional peptides: AT1002, which is a tight junction modulator and 6-mer synthetic peptide belonging to a novel class of compounds that reversibly increases paracellular transport of molecules across the epithelial barrier; and Tat, which is a cell-penetrating peptide applicable as a transdermal siRNA delivery enhancer. We examined whether expression of the tight junction protein zonula occludens protein 1 (ZO-1) was detected in mouse skin applied with AT1002. Additionally, siRNA stabilities for RNaseA using Tat and AT1002 were assessed. We also determined the intradermal delivery efficiency of siRNA using functional peptides by confocal laser microscopy of fluorescently labeled siRNA in mouse skin. We found that the Tat analog and AT1002 strongly increased siRNA stability against RNaseA. In addition, ZO-1 disappeared from the skin after treatment with AT1002, yet recovered with time after washing. Finally, we also found that Tat and AT1002 peptides accelerate transdermal siRNA delivery both widely and effectively. Thus, combination of Tat and AT1002 is expected to be a transdermal delivery enhancer of siRNA.

Label-free discrimination of tumorigenesis stages using in vitro prostate cancer bone metastasis model by Raman imaging

Metastatic prostate cancer colonizes the bone to pave the way for bone metastasis, leading to skeletal complications associated with poor prognosis and morbidity. This study demonstrates the feasibility of Raman imaging to differentiate between cancer cells at different stages of tumorigenesis using a nanoclay-based three-dimensional (3D) bone mimetic in vitro model that mimics prostate cancer bone metastasis. A comprehensive study comparing the classification of as received prostate cancer cells in a two-dimensional (2D) model and cancer cells in a 3D bone mimetic environment was performed over various time intervals using principal component analysis (PCA). Our results showed distinctive spectral differences in Raman imaging between prostate cancer cells and the cells cultured in 3D bone mimetic scaffolds, particularly at 1002, 1261, 1444, and 1654 cm-1, which primarily contain proteins and lipids signals. Raman maps capture sub-cellular responses with the progression of tumor cells into metastasis. Raman feature extraction via cluster analysis allows for the identification of specific cellular constituents in the images. For the first time, this work demonstrates a promising potential of Raman imaging, PCA, and cluster analysis to discriminate between cancer cells at different stages of metastatic tumorigenesis.

Type 2 diabetes detection based on serum sample Raman spectroscopy

In this work, we propose to the Raman spectroscopy as a new technique for the detection of the type 2 diabetes using blood serum samples. The serum samples were obtained from 15 patients who were clinically diagnosed with type 2 diabetes mellitus and 20 healthy volunteers. The average spectra showed equally intense peaks as, 695 cm-1, the doublet of tyrosine at 828 and 853 cm-1, phenylalanine at 1002 and 1028 cm-1, the phospholipid shoulder at 1300-1345 cm-1, and proteins (amide I) at 1654 cm-1. The major differences were found at 661 and 1404 cm-1 (glutathione), 714 (polysaccharides), 605 (Phe), 545 cm-1 (tryptophan), and the shoulder of amide III at 1230-1282 cm-1, where seem to disappear in the diabetes spectrum. On the contrary, the region that is more highlighted due to that diabetes peaks are clearly more intense was 897-955 cm-1. Principal component analysis and linear discriminate analysis were employed for developing discrimination method. The first three principal components provided a classification of the samples from healthy and diabetes patients with high sensitivity and specificity. In addition, when the first principal component was plotted as a function of the Raman shift, it revealed these shifts accounted for the greatest differences between control and diabetes samples, which coincided with the shifts of spectral differences shown by mean spectra. Our results demonstrated that serum sample Raman spectroscopy promises to become a non-invasive support tool of the currently applied techniques for type 2 diabetes detection, decreasing the false-positive cases.